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Abstract
Gestational diabetes mellitus (GDM) is associated with short- and long-term 
complications in both mothers and their offspring. Screening and early diagnosis of 
GDM is advocated as a strategy to prevent adverse pregnancy outcomes. However, 
there is currently no test that is amenable to routine screening, particularly in 
low-and middle-income countries. MicroRNAs (miRNAs) are small non-coding 
RNA molecules that regulate gene expression post-transcriptionally. In recent 
years, miRNAs have been the focus of increasing research due to their important 
role in regulating biological pathways and their aberrant expression during disease. 
The discovery of circulating miRNAs in maternal blood, and their altered expres-
sion during pregnancy-associated complications have increased interest into their 
potential as diagnostic biomarkers for GDM. In this review, we summarise studies 
that have investigated miRNAs in maternal blood thus providing an update of the 
current status of miRNAs as biomarkers for GDM. We also discuss the challenges of 
miRNA profiling, and highlight perspectives and recommendations for research.
Keywords: gestational diabetes mellitus, biomarkers, epigenetics, microRNAs, 
pregnancy
1. Introduction
Gestational diabetes mellitus (GDM) is defined as glucose intolerance that is 
first diagnosed during pregnancy with glucose homeostasis usually restored shortly 
after birth. The rate of GDM has constantly increased over the last 20 years [1], and 
in 2017 the International Diabetes Federation estimated that about 14% of women 
with live births had GDM [2]. Without appropriate glucose management, GDM 
is associated with short- and long-term complications in both mothers and their 
offspring [3–6]. Treatment of GDM is effective in preventing these adverse outcomes 
[7–11], thus, universal screening and early detection of GDM is widely advocated as 
a strategy to promote timely treatment and improve pregnancy outcomes [3]. The 
oral glucose tolerance test (OGTT) conducted between the 24th and 28th week of 
pregnancy, is currently the gold standard for GDM diagnosis [12]. However, the test 
is time-consuming, expensive and unfeasible in most countries. The identification 
of simple and cost-effective biomarkers that do not require fasting and multiple 
blood draws would be more acceptable to pregnant women, and thereby facilitate 
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screening for GDM. MicroRNAs (miRNAs) are small noncoding RNA molecules that 
regulate various metabolic pathways. They are implicated in the pathophysiology of 
various diseases and have attracted considerable interest as biomarkers of metabolic 
disease. Recently, several studies have explored their potential as biomarkers of 
GDM. The purpose of this review is to provide an update of the status of miRNAs as 
biomarkers for GDM. All studies that have profiled miRNAs in maternal blood dur-
ing GDM to date are summarised. We also discuss the challenges of miRNA research, 
and highlight perspectives and recommendations for future research.
2. Overview of gestational diabetes
Hyperglycaemia during pregnancy creates an adverse intrauterine environ-
ment that predisposes both mother and offspring to perinatal complications and 
future metabolic disease [3–6]. Maternal perinatal complications include caesarean 
section, preeclampsia and birth injuries. Women with pregnancies complicated by 
GDM also have an increased risk of developing disease in later life. In 2009, Bellamy 
et al. conducted a comprehensive review of the literature and found that women 
who have had GDM are at least seven-fold more likely to develop Type 2 diabetes 
(T2D) compared to women with normoglycaemic pregnancies [4]. Other studies 
showed that GDM is associated with the development of metabolic disease [13], 
cardiovascular disease [14] and breast cancer [15].
Foetal and neonatal complications associated with GDM include macrosomia, 
congenital malformations, perinatal death, hypertrophic cardiomyopathy, intrauter-
ine growth restriction, preterm birth, respiratory distress syndrome, hypoglycaemia, 
hypocalcaemia, polycythaemia and hyperbilirubinemia [5]. In recent years, increas-
ing evidence support the critical role of the intrauterine environment in program-
ming the foetus and influencing long-term offspring health [16]. In the 1980s, David 
Barker and his colleagues proposed Barker’s hypothesis or the developmental origins of 
adult disease, which suggests that metabolic diseases have their origins in early devel-
opment [17]. Subsequently, several other studies have reported that diabetes during 
pregnancy is associated with the development of obesity and diabetes in children [5].
The prevalence of GDM is rapidly increasing, spurred by the global obesity pan-
demic. Pregnant women who are overweight, obese or severely obese have a 2.14-, 
3.56- and 8.56-fold risk of developing GDM compared to normal weight women 
[18]. The short- and long-term consequences of GDM are likely to have a major 
negative impact, particularly on low- and middle-income countries that already 
have limited financial and human resources, and are least able to respond to the 
challenge. Screening and treatment of GDM leads to improved pregnancy outcomes 
[7–11], thus universal screening for GDM is widely advocated as a strategy to pre-
vent pregnancy complications. However, the OGTT, which is considered the gold 
standard for GDM diagnosis is not amenable to routine screening [3]. Currently, 
traditional risk-factor screening based on obesity, age older than ≥35 years, non-
white ethnicity, and having a family history of diabetes [3] is mostly employed. 
Unfortunately, these risk factors have poor predictive value [19, 20]. A number of 
other laboratory tests such as glycated haemoglobin (HbA1c), insulin, adiponectin, 
glycosylated fibronectin and C-reactive protein have been explored, however, they 
too have several challenges and are not yet clinically applicable [3].
3. Characteristics of ideal biomarkers
Biomarkers are defined as “cellular, biochemical or molecular alterations that 
are measurable in biological media such as human tissues, cells or fluids” [21]. 
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Screening, diagnostic and prognostic biomarkers offer several advantages and thus 
efforts to identify biomarkers of disease have intensified. They are clinically useful 
and can be used to detect or monitor disease progression, thus facilitating earlier 
diagnosis and disease management. Furthermore, biomarkers are able to monitor 
pharmacological responses and predict clinical outcome. As recently reviewed 
by Etheridge et al. [22], characteristics of the ideal biomarker include sensitivity, 
specificity, cost-effectiveness, reproducibility, robustness, accessibility, stability 
and ability to differentiate between pathologies. Recent advancements in molecular 
biology have led to the development of molecular biomarkers that are sensitive and 
specific, and are easily measured in biological fluids such as whole blood, plasma 
and serum [22].
4. MicroRNAs
MiRNAs are epigenetic mechanisms that reflect gene-environment interactions 
and are increasingly being implicated in the pathophysiology of metabolic diseases 
[23]. Since their discovery in Caenorhabditis elegans in 1993 [24], miRNAs have 
emerged as one of the most powerful epigenetic mechanisms regulating diverse 
biological processes including development, proliferation, differentiation and 
apoptosis [25]. They are short, single-stranded, highly conserved, non-coding RNA 
molecules of approximately 22 nucleotides in length that regulate gene expression 
through post-transcriptional mechanisms. MiRNAs bind to the 3′ untranslated 
region (UTR) of messenger RNA (mRNA) inducing degradation or translational 
repression of the mRNA transcript [26]. Using an elegant set of experiments, Guo 
et al. showed that destabilisation of target mRNAs rather than translational repres-
sion is the main mechanism whereby miRNAs reduce protein expression [26]. A 
single miRNA is able to regulate up to 200 target genes, implying that about 30% of 
the genome is regulated by miRNAs [27, 28] and confirming the important role of 
miRNAs as mediators of biological function. More than 2000 miRNAs are present 
in the human genome, and function in various biological processes [27–29].
Mature miRNAs are produced through a stepwise process. Briefly, primary 
miRNA transcripts (pri-miRNAs) are transcribed in the nucleus by RNA poly-
merase II (and possibly by RNA polymerase III), which are then cleaved by Drosha 
RNase III endonuclease to produce stem-loop precursor miRNAs (pre-miRNAs) 
that are approximately 70 nucleotides long. Ran-GTP and the export receptor, 
Exportin-5 transports pre-miRNAs to the cytoplasm, where Dicer, also a RNase III 
endonuclease, cleaves them to produce mature miRNAs. Mature miRNAs complex 
with the RNA-induced silencing complex (RISC) and bind to the 3’ UTR of mRNA 
to induce predominantly mRNA degradation [25, 26].
MiRNAs regulate a wide range of biological processes including cell proliferation 
and differentiation, apoptosis and metabolism, thus it is not surprising that altered 
miRNA expression have been shown to associated with various conditions including 
cancer, obesity, T2D and cardiovascular disease [30]. MiRNAs play a critical role in 
the pathophysiology of metabolic disease, and their aberrant expression is observed 
in tissues associated with disease. For example, various in vitro, in vivo animal 
models and studies in diabetic patients have demonstrated the altered expression 
of miRNAs that regulate insulin secretion, adipocyte differentiation, lipid metabo-
lism, inflammation and glucose homeostasis in dysfunctional pancreatic beta cells 
and insulin-resistant target tissues, such as adipose, liver and muscle during T2D 
[23]. Increasingly evidence show that correcting aberrant miRNA expression can 
prevent or treat T2D, making them attractive therapeutic targets [31].
The identification of circulating miRNAs in biological fluids such as whole 
blood, serum, plasma and urine has sparked research efforts to investigate their 
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feasibility as diagnostic or prognostic biomarkers of disease [32–34]. Circulating 
miRNAs are speculated to reflect tissue expression, to play a central role in cell-to-
cell communication and to be associated with disease progression [33–35]. Other 
attributes that make miRNAs attractive biomarkers is their stability and robust 
expression [22], even in degraded RNA samples [36]. Technological advances and 
the development of various platforms for miRNA profiling have bolstered the popu-
larity of miRNAs [37], and have enabled relative easy and cost-effective methods of 
quantification using sensitive techniques such as quantitative real time PCR (qRT-
PCR) [22, 32, 38]. Circulating miRNAs are thought to be released from cells as exo-
somes, microvesicles, apoptotic bodies, or are non-vesicle bound and encapsulated 
in protein or lipid complexes [32]. A number of studies [39–41], have demonstrated 
that circulating miRNAs are associated with glucose homeostasis and are dysregu-
lated during T2D progression. Recently, we showed that the expression of miR-27b 
is increased in peripheral blood cells and serum of South African women with 
impaired glucose tolerance compared to normoglycaemia [42] and identified novel 
miRNAs associated with dysglycaemia in these women [43]. Putative gene targets of 
these novel miRNAs were enriched in biological processes involved in key aspects of 
glucose regulation, and receiver operating characteristic (ROC) curve analysis dem-
onstrated that the diagnostic utility of these miRNAs were similar to fasting insulin 
[43]. Intriguingly, Parrizas et al. showed that an exercise intervention was able to 
reverse the aberrant expression of miR-192 and miR-193b induced by impaired 
glucose tolerance [44], while Luo et al. [45] showed that platelet-derived miR-126 
was altered during T2D progression, and that glucose lowering treatment was able 
to normalise its expression. These studies provide support for the use of miRNAs as 
diagnostic and prognostic biomarkers to monitor treatment response.
5. MicroRNAs, pregnancy and gestational diabetes
MiRNAs play an important role as metabolic and developmental regulators 
during pregnancy. They respond to changing physiological conditions during preg-
nancy, while their dysregulation contributes to pregnancy-related disorders [46]. 
Thus far over 600 placental miRNAs have been identified [47]. Altered placental 
miRNA expression has been demonstrated in several pregnancy related disorders. 
In 2007, Pineles et al. were the first to demonstrate altered miRNA expression dur-
ing preeclampsia. They reported that the expression of two miRNAs, miR-210 and 
miR-182, were increased during preeclampsia [48]. In 2009, using microarrays, Hu 
et al. and Zhu et al. identified seven and 34 miRNAs, respectively, that are dys-
regulated in preeclamptic compared to normal pregnancies [49, 50]. Subsequently, 
other studies have reported differential miRNA expression during preeclampsia and 
importantly provide experimental evidence to support the involvement of these 
miRNAs in disease pathophysiology [51, 52]. Altered miRNA expression has also 
been observed in other pregnancy complications such as macrosomia [53], preterm 
delivery and small for gestational age [54].
Placental-derived miRNAs in maternal blood have potential as biomarkers for 
pregnancy monitoring [54, 55]. It is suggested that miRNAs from placental tissue 
are exported into the maternal circulation via exosomes, and that these miRNAs 
reflect the physiological status of pregnancy and may thus have diagnostic potential 
[56]. Many of studies have reported that maternal circulating miRNAs are associ-
ated with placental weight [57], placental dysfunction [58, 59] and pregnancy 
complications [54, 60–63]. MiR-517c was increased in pregnancies complicated 
with placental abruption [59], miR-515, miR-516a, miR-516b, miR-518b, miR-519d, 
miR-520a, miR-520h, miR-525, miR-526b and miR-1323 were increased during 
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preeclampsia [63], miR-516, miR-517, miR-520a, miR-525 and miR-526a were 
upregulated during preeclampsia, gestational hypertension and foetal growth 
restriction [60], miR-517a was increased and miR-518b was decreased during pla-
centa previa [58], and miR-346 and miR-582 were increased during preeclampsia, 
preterm delivery and small for gestational age patients compared to normal con-
trols [54]. Importantly, Hromadnikova et al. showed that upregulation of plasma 
miR-517, miR-518b and miR-520h during the first trimester was associated with the 
development of preeclampsia, and provided evidence to suggest that miR-517 could 
predict preeclampsia [61]. Furthermore, a number of studies have reported that cir-
culating miRNAs are associated with macrosomia [62, 64, 65]. Jiang and colleagues 
demonstrated that maternal expression of miR-21, and to a lesser extent miR-20a 
in serum samples from pregnant women in the third trimester was associated with 
macrosomia [62], Hu et al. reported that macrosomia was associated with decreased 
serum expression of miR-376a [64], while Ge et al. reported that the expression of 
miR-18a, miR-141, miR-143, miR-200c and miR-221 were decreased, and miR-16, 
miR-30a and miR-523 were increased in the plasma of pregnant women with foetal 
macrosomia compared to normal controls [65], further supporting the use of 
miRNAs as predictive biomarkers for pregnancy complications.
Growing evidence implicate miRNAs in the pathogenesis of GDM [47] and 
suggest that maternal miRNA expression may be used as biomarkers to predict 
GDM. Indeed, many GDM associated miRNAs are also expressed in placentas of 
women with Type 1 diabetes and T2D, confirming that miRNAs expressed during 
GDM play an important role in metabolic regulation and reflects some of the shared 
aetiology between these different types of diabetes [66]. Interestingly, a subset 
of miRNAs were distinct for each type of diabetes, illustrating their potential to 
differentiate between GDM and other manifestations of diabetes. Several other 
studies have reported that placental miRNA expression is altered in women with 
GDM. Zhao et al. reported that miR-518d is upregulated in placentas of women 
with GDM compared to controls, and further showed that increased expression of 
miR-518d correlated with decreased protein expression of peroxisome proliferator-
activated receptor-α (PPARα) [67], a major regulatory transcription factor in lipid 
homeostasis and energy metabolism [68, 69]. Li et al. identified nine miRNAs 
that are dysregulated in placentas of women with GDM, the expression of miR-
508 was increased and miR-9, miR-27a, miR-30d, miR-33a, miR-92a, miR-137, 
miR-362 and miR-502 were decreased. Importantly, the decreased expression of 
these miRNAs correlated with increased protein expression of their gene targets, 
epidermal growth factor receptor (EGFR), phosphoinositide 3-Kinase (PI3K) and 
protein kinase B (Akt), key proteins in placental development and foetal growth 
[70]. Other studies showed that miR-98 [71] and miR-503 [72] are upregulated 
and miR-143 is downregulated [73] in placentas of women with GDM compared to 
women with normoglycaemic pregnancies. Intriguingly, the expression of miR-143 
differentiated between GDM managed by diet or medication [71], further support-
ing the clinical value of miRNAs.
Xu et al. showed that the increased expression of miR-503 in the placentas of 
women with GDM compared to normoglycaemic pregnancies, are reflected in 
plasma [72]. The studies that have quantified circulating miRNA expression during 
GDM are summarised in Table 1. In 2011, Zhao et al. were the first to profile the 
expression of serum miRNAs during GDM [74]. Using Taqman low density arrays, 
followed by confirmation with individual qRT-PCR, they found that serum expres-
sion of miR-29a, miR-132 and miR-222 were decreased during GDM. Importantly, 
these results were validated in an internal and external cohort. Notably, serum for 
miRNA profiling in the discovery cohort was collected at 16–19 weeks of preg-
nancy, while GDM was diagnosed at 24–28 weeks of pregnancy, thus illustrating 
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GDM/ 
controls
Bio 
logical 
source
Detection 
method
Up- 
regulated
Down-
regulated
No 
change
Normali 
sation
Ref
24/24*
(16–
19 weeks 
gestation)
Serum Taqman 
low density 
array
qRT-PCR
– miR-29a
miR-132
miR-222
– Cel-
miR-39
[74]
28/53
(13–
31 weeks 
gestation)
Serum qRT-PCR – miR-20a
miR-222
miR-16
miR-17
miR-19a
miR-19b
miR-29a
miR-132
Cel-
miR-39
[75]
13/9
(23–
31 weeks 
gestation)
Plasma qRT-PCR let-7e
let-7 g
miR-100
miR-101
miR-146a 
miR-8a
miR-195
miR-222
miR-23b
miR-30b
miR-30c
miR-30d
miR-342
miR-423
miR-92a
– – Cel-
miR-39
[76]
36/80
(7–23 weeks 
gestation)
Plasma qRT-PCR miR-155
miR-21
miR-
146b 
miR-517
miR-222
miR-210
miR-518a
miR-29a
miR-223
miR-126
Cel-
miR-39 
and 
miR-423
[77]
10/10
(16–
19 weeks 
gestation)
Plasma Sequencing 
qRT-PCR
miR-16
miR-17
miR-19a
miR-19b
miR-20a
– – miR-221 [78]
85 GDM 
and 72 
controls 
(16–20, 
20–24 and 
24–28 weeks 
gestation)
Plasma qRT-PCR miR-16
miR-17
miR-20a
– miR-19a
miR-19b
RNU6 [79]
21/10
(24–
33 weeks 
gestation)
Plasma qRT-PCR miR-330 – miR-
548c
miR-374
miR-320
[92]
30/30 (24–
32 weeks 
gestation)
Whole 
blood
Sequencing
qRT-PCR
miR-340 – – RNU6B [93]
20/20
NK
Whole
blood
qRT-PCR – miR-494 – RNU6 [94]
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the potential of these miRNAs as screening tools for GDM. Recently, Pheiffer et al. 
reported that the expression of miR-29a, miR-132 and miR-222 were similarly 
decreased in the serum of South African women with GDM, however, only the 
latter was statistically significant [75]. Conflictingly, Tagoma et al. showed that 
miR-222 was increased in plasma of women with GDM compared to normogly-
caemic pregnancies [76]. Moreover, Wander et al., observed no differences in the 
expression of miR-29a and miR-222 in the plasma of American women with or 
without GDM [77], thus illustrating the heterogeneity of miRNA expression.
In 2015, Zhu et al. used high-throughput sequencing and qRT-PCR to investigate 
miRNAs in plasma samples of Chinese women with or without GDM [78]. Five 
miRNAs (miR-16, miR-17, miR-19a, miR-19b and miR-20a) were significantly 
upregulated in women with GDM compared to controls. Furthermore, the differen-
tial expression of these miRNAs were observed at 16–19 weeks of pregnancy, before 
GDM diagnosis, once again illustrating the diagnostic value of miRNAs [78]. Cao 
et al. similarly demonstrated increased expression of plasma miR-16, miR-17 and 
miR-20a in a larger cohort of Chinese women, however, they did not observe differ-
ences in the expression of miR-19a and miR-19b [79]. More recently, Pheiffer et al. 
reported conflicting results. The expression of all five miRNAs were decreased in 
South African women with GDM, however, only the decreased expression of miR-20a 
was statistically significant [75]. Interestingly, regression analysis showed that miR-
20a was a significant predictor of GDM, while age and body mass index were not.
Although these miRNAs were identified in plasma or serum, bioinformatics [75, 
78] and experimental [74] functional analyses provided support for their biologi-
cal relevance and role in the pathogenesis of GDM. Other studies also confirm the 
importance of miRNAs during GDM. For example, in 2014, Shi et al. reported that 
the expression of miR-222 is increased in omental tissue from women with GDM 
compared to women with normoglycaemic pregnancies, and conducted elegant 
in vitro experiments to demonstrate that miR-222 potentially regulates oestrogen-
induced insulin resistance during GDM. As shown in Table 1, many more miRNAs 
have been reported to exhibit altered expression in maternal blood during GDM, 
however, these were investigated in single studies only.
6. Gestational diabetes and foetal microRNA expression
Dysregulated miRNA expression has been reported in human umbilical vein 
endothelial cells (HUVECs) of foetuses exposed to GDM. Floris et al. reported that 
GDM/ 
controls
Bio 
logical 
source
Detection 
method
Up- 
regulated
Down-
regulated
No 
change
Normali 
sation
Ref
67/74
(16–20, 
20–24 and 
24–28)
Serum qRT-PCR miR-183
miR-200b 
miR-125b
miR-1290
– – Cel-
miR-39
[95]
11/12 (third 
trimester)
Plasma qRT-PCR miR-137 – – RNU6 [81]
25/25
NK
Plasma qRT-PCR miR-503 – – NK [72]
*Validated in internal (36 GDM/36 controls) and two external cohorts (16 GDM/16 controls each).
GDM: gestational diabetes mellitus; qRT-PCR: quantitative real time polymerase chain reaction; NK: not known.
Table 1. 
Studies investigating microRNA expression in maternal blood during gestational diabetes mellitus.
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impaired HUVEC function during GDM is associated with altered miR-101 expres-
sion [80]. Several other miRNAs, miR-137 [81], miR-let-7a, miR-let-7g, miR-30c, 
miR-126, miR-130b, miR-148a and miR-452 [82] were upregulated in HUVECs 
from infants born to mothers with GDM, suggesting that miRNAs reflect the 
adverse in utero environment imposed by GDM. Tryggestad et al. further showed 
that two of these miRNAs, miR-130b and miR-148a, target and decrease the expres-
sion of 5′ Adenosine monophosphate-activated protein kinase (AMPKα1), whose 
protein expression is decreased in placenta exposed to GDM [82]. Recently, altered 
miRNA expression in offspring blood was shown to be associated with birth weight 
[83]. MiR-33b and miR-375 were overexpressed during macrosomia, while miR-454 
was overexpressed in blood of both low birth weight and macrosomic compared 
to normal birth weight offspring [83]. Aberrant miR-346 and miR-582 expression 
in cord blood were shown to be associated with foetal complications [54]. Taken 
together, these studies provide evidence that GDM induces dysregulated miRNA 
expression in offspring, which may predispose them to metabolic disease in later 
life. Thus, miRNAs offer potential to predict disease in offspring, which could facili-
tate intervention strategies to prevent future disease.
7. Challenges of microRNA profiling
Despite their stability and relative ease of quantification, analysis of circulating 
miRNAs present several pre-analytical and analytical challenges [84] that must 
be addressed before they can be used clinically. Many studies have reported that 
miRNA expression is affected by sample type, method of miRNA extraction, and 
quantification and data normalisation strategies. Differences in miRNA expres-
sion between whole blood and serum [42], between different cell types in whole 
blood [85, 86], between plasma and serum [87, 88] and between placenta, plasma 
and cord blood [54] have been described. Furthermore, miRNA expression varies 
according to the extraction kit used [88]. Currently, qRT-PCR is considered the 
gold standard for miRNA analysis, however variations between qRT-PCR platforms 
[87] and between qRT-PCR and other measurement platforms [22, 42, 87, 88] have 
been widely reported. Furthermore, data normalisation is a significant challenge 
during miRNA profiling, particularly extracellular miRNAs [89]. Currently, there 
is no consensus on the best normalisation strategy to use when profiling circulat-
ing miRNAs, although strategies based on exogenous spike-in-controls such as C. 
elegans miR-39 have been shown to be less variable than using endogenous miRNAs 
[88]. Moreover, heterogeneous miRNA expression is observed between populations, 
mediated by both genetic and environmental factors [90, 91]. During pregnancy, 
gestation time is also reported to affect miRNA expression [55]. Lastly, miRNAs are 
non-specific. For example, a single miRNA can regulate up to 200 different genes 
[27, 28], thus miRNAs found to be associated with GDM, may possibly be involved 
in other conditions as well.
8. Perspectives and recommendations for future research
MiRNAs offer great potential as biomarkers for GDM. However, they face many 
challenges that need to be addressed before they can become clinically applicable. 
Standardisation of pre-analytical and analytical methods for miRNA research may 
minimise the lack of reproducibility between studies and should be prioritised 
in miRNA research [22]. MiRNAs are epigenetic mechanisms that are regulated 
by various factors [90, 91], which need to be considered in miRNA studies. Large 
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prospective cohort studies should be conducted to elucidate how biological, genetic 
and environmental factors affect miRNA expression, and to identify plausible 
diagnostic or prognostic candidates. Moreover, due to their non-specificity [27, 28], 
it is recommended that a panel of miRNAs, either alone, or in combination with 
other risk factors, should be used to increase the specificity of risk stratification 
models for GDM.
9. Conclusions
In this review the current status of miRNAs as biomarkers for GDM was dis-
cussed, together with recommendations for research. We provide evidence to show 
that miRNAs possess tremendous potential as routine screening tools, which could 
facilitate earlier diagnosis and management of GDM with dietary modifications or 
therapeutic intervention. A growing number of studies have demonstrated their 
clinical utility, and technological advances can lead to the development of inex-
pensive, point-of-care miRNA diagnostic tests in the future. However, at present 
miRNA profiling during GDM remains inconclusive, largely due to the irreproduc-
ibility of results between studies. Many technical, analytical and biological chal-
lenges hamper miRNA research, and must be addressed before these small RNA 
molecules, which are master regulators of gene expression, can become clinically 
applicable.
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